Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of RO7446603 alone or in combination with aflibercept or faricima…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Eylea (aflibercept) (aflibercept)
• RO7446603
• Vabysmo (faricimab) (faricimab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Diabetic Macular Edema | Phase 1, Phase 2 | Status: RECRUITING